Phaarmasia Limited (PHRMASI) Share Price
BSE · Healthcare · Drug Manufacturers - Specialty & Generic · ISIN INE486I01016
Key metrics
- Market Cap
- ₹65 Cr
- P/E Ratio
- 3.68
- EPS
- 25.84
- Book Value
- 32.37
- P/B Ratio
- 2.94
- ROE
- 79.53%
- ROCE
- 7.15%
- Debt / Equity
- 0.05
- Net Margin
- 37.22%
- Revenue Growth
- 93.72%
- Profit Growth
- 1,205.62%
- Dividend Yield
- —
- 52W High
- ₹131.75
- 52W Low
- ₹30.01
- Market Cap Band
- micro cap
- Face Value
- —
Ratios computed from the annual results period ending 2026-03-31.
About Phaarmasia Limited
Phaarmasia Limited manufactures and sells oral contraceptive pills and iron tablets in India. It offers hormone products, including mifepristone and misoprostaol, desogestrel and ethinyl estradiol, estradiol valerate, levonorgestrel and ethinyl estradiol, medroxyprogesterone acetate, cabergoline, clomiphene citrate, levonorgestrel, progesterone, fluoxymesterone, liothyronine sodium, chlorodehydromethyltestosterone, liothyronine sodium, oxandrolone tablets, testosterone cypionate, methenolone enanthate, drostanolone, testosterone, trenbolone, and stanozolol cypionate injections. The company provides herbal products, such as herbal toothpaste, cough and sore throat reliver, and mouth ulcer gel under the Smyle brand name. Phaarmasia Limited was incorporated in 1981 and is based in Hyderabad, India.
- Headquarters
- Hyderabad, India
- Promoter Holding
- 80.11%
The full Phaarmasia Limited analysis
Create a free account to open the complete PHRMASI deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.
- 10-year financialsIncome statement, balance sheet and cash flow, year by year.
- Valuation & fair valueFair-value estimates, quality scores and a value grade.
- Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
- Shareholding historyPromoter, FII, DII and public holdings across every quarter.
- Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
- Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.